rse shall
verified
for one
nursing
tion;
nized by
ursing;
read the
provided
ng to an
ooard or
eets the
gistered
certified
and
practice
oard.
gistered
gistered

Page 1 of 13

22 RS HB 354/GA

1

2

nurse in this state and maintain current certification by the appropriate national organization or agency recognized by the board.

3 (5) Any person who holds a license to practice as an advanced practice registered nurse
4 in this state shall have the right to use the title "advanced practice registered nurse"
5 and the abbreviation "APRN." No other person shall assume the title or use the
6 abbreviation or any other words, letters, signs, or figures to indicate that the person
7 using the same is an advanced practice registered nurse. No person shall practice as
8 an advanced practice registered nurse unless licensed under this section.

9 (6) Any person heretofore licensed as an advanced practice registered nurse under the 10 provisions of this chapter who has allowed the license to lapse may be reinstated on 11 payment of the current fee and by meeting the provisions of this chapter and 12 regulations promulgated by the board pursuant to the provisions of KRS Chapter 13 13A.

14 (7) The board may authorize a person to practice as an advanced practice registered
15 nurse temporarily and pursuant to applicable regulations promulgated by the board
16 pursuant to the provisions of KRS Chapter 13A if the person is awaiting licensure
17 by endorsement.

Except as authorized by subsection (9) of this section, before an advanced 18 (8) (a) 19 practice registered nurse engages in the prescribing or dispensing of 20 nonscheduled legend drugs as authorized by KRS 314.011(8), the advanced 21 practice registered nurse shall enter into a written "Collaborative Agreement 22 for the Advanced Practice Registered Nurse's Prescriptive Authority for 23 Nonscheduled Legend Drugs" (CAPA-NS) with a physician licensed in 24 Kentucky that defines the scope of the prescriptive authority for nonscheduled 25 legend drugs.

(b) The advanced practice registered nurse shall notify the Kentucky Board of
Nursing of the existence of the CAPA-NS and the name of the collaborating

Page 2 of 13

22 RS HB 354/GA

physician and shall, upon request, furnish to the board or its staff a copy of the
 completed CAPA-NS. The Kentucky Board of Nursing shall notify the
 Kentucky Board of Medical Licensure that a CAPA-NS exists and furnish the
 collaborating physician's name.

- 5 (c) The CAPA-NS shall be in writing and signed by both the advanced practice 6 registered nurse and the collaborating physician. A copy of the completed 7 collaborative agreement shall be available at each site where the advanced 8 practice registered nurse is providing patient care.
- 9 (d) The CAPA-NS shall describe the arrangement for collaboration and 10 communication between the advanced practice registered nurse and the 11 collaborating physician regarding the prescribing of nonscheduled legend 12 drugs by the advanced practice registered nurse.
- (e) The advanced practice registered nurse who is prescribing nonscheduled
 legend drugs and the collaborating physician shall be qualified in the same or
 a similar specialty.
- 16 (f) The CAPA-NS is not intended to be a substitute for the exercise of 17 professional judgment by the advanced practice registered nurse or by the 18 collaborating physician.
- (g) The CAPA-NS shall be reviewed and signed by both the advanced practice
 registered nurse and the collaborating physician and may be rescinded by
 either party upon written notice to the other party and the Kentucky Board of
 Nursing.
- (9) (a) Before an advanced practice registered nurse may discontinue or be exempt
 from a CAPA-NS required under subsection (8) of this section, the advanced
 practice registered nurse shall have completed four (4) years of prescribing as
 a <u>certified</u> nurse practitioner, clinical nurse specialist, <u>certified</u> nurse midwife,
 or as a certified registered nurse anesthetist. For certified nurse practitioners

22 RS HB 354/GA

1		and clinical nurse specialists, the four (4) years of prescribing shall be in a
2		population focus as defined in KRS 314.011.
3	(b)	After four (4) years of prescribing with a CAPA-NS in collaboration with a
4		physician:
5		1. An advanced practice registered nurse whose license is in good standing
6		at that time with the Kentucky Board of Nursing and who will be
7		prescribing nonscheduled legend drugs without a CAPA-NS shall notify
8		that board that the four (4) year requirement has been met and that he or
9		she will be prescribing nonscheduled legend drugs without a CAPA-NS;
10		2. The advanced practice registered nurse will no longer be required to
11		maintain a CAPA-NS and shall not be compelled to maintain a CAPA-
12		NS as a condition to prescribe after the four (4) years have expired, but
13		an advanced practice registered nurse may choose to maintain a CAPA-
14		NS indefinitely after the four (4) years have expired; and
15		3. If the advanced practice registered nurse's license is not in good
16		standing, the CAPA-NS requirement shall not be removed until the
17		license is restored to good standing.
18	(c)	An advanced practice registered nurse wishing to practice in Kentucky
19		through licensure by endorsement is exempt from the CAPA-NS requirement
20		if the advanced practice registered nurse:
21		1. Has met the prescribing requirements in a state that grants independent
22		prescribing to advanced practice registered nurses; and
23		2. Has been prescribing for at least four (4) years.
24	(d)	An advanced practice registered nurse wishing to practice in Kentucky
25		through licensure by endorsement who had a collaborative prescribing
26		agreement with a physician in another state for at least four (4) years is
27		exempt from the CAPA-NS requirement.

Page 4 of 13

- 1 Except as provided in subsections (13) and (14) of this section, before an (10) (a) 2 advanced practice registered nurse engages in the prescribing of Schedules II 3 through V controlled substances as authorized by KRS 314.011(8), the 4 advanced practice registered nurse shall enter into a written "Collaborative 5 Agreement for the Advanced Practice Registered Nurse's Prescriptive 6 Authority for Controlled Substances" (CAPA-CS) with a physician licensed in 7 Kentucky that defines the scope of the prescriptive authority for controlled 8 substances.
- 9 (b) The advanced practice registered nurse shall notify the Kentucky Board of 10 Nursing of the existence of the CAPA-CS and the name of the collaborating 11 physician and shall, upon request, furnish to the board or its staff a copy of the 12 completed CAPA-CS. The Kentucky Board of Nursing shall notify the 13 Kentucky Board of Medical Licensure that a CAPA-CS exists and furnish the 14 collaborating physician's name.
- 15 (c) The CAPA-CS shall be in writing and signed by both the advanced practice 16 registered nurse and the collaborating physician. A copy of the completed 17 collaborative agreement shall be available at each site where the advanced 18 practice registered nurse is providing patient care.
- (d) The CAPA-CS shall describe the arrangement for collaboration and
 communication between the advanced practice registered nurse and the
 collaborating physician regarding the prescribing of controlled substances by
 the advanced practice registered nurse.
- (e) The advanced practice registered nurse who is prescribing controlled
 substances and the collaborating physician shall be qualified in the same or a
 similar specialty.
- 26 (f) The CAPA-CS is not intended to be a substitute for the exercise of 27 professional judgment by the advanced practice registered nurse or by the

22 RS HB 354/GA

1		collaborating physician.
2	(g)	[Before engaging in the prescribing of controlled substances, the advanced
3		practice registered nurse shall:
4		1. Have been licensed to practice as an advanced practice registered nurse
5		for one (1) year with the Kentucky Board of Nursing; or
6		2. Be nationally certified as an advanced practice registered nurse and be
7		registered, certified, or licensed in good standing as an advanced
8		practice registered nurse in another state for one (1) year prior to
9		applying for licensure by endorsement in Kentucky.
10	(h)	
11		nurse shall obtain a Controlled Substance Registration Certificate through the
12		<u>United States</u> [U.S.] Drug Enforcement <u>Administration[Agency]</u> .
13	<u>(h)</u> {	(i)] The CAPA-CS shall be reviewed and signed by both the advanced
14		practice registered nurse and the collaborating physician and may be rescinded
15		by either party upon written notice to the other party and the Kentucky Board
16		of Nursing.
17	<u>(i)</u> {(j)] The CAPA-CS shall state the limits on controlled substances which may
18		be prescribed by the advanced practice registered nurse, as agreed to by the
19		advanced practice registered nurse and the collaborating physician. The
20		CAPA-CS may include any limitations on drugs and amounts that may be
21		prescribed, as well as any requirements for the advanced practice registered
22		nurses to communicate with the collaborating physician before prescribing
23		a controlled substance. These agreements may be individualized to
24		accommodate variations in practice. The limits so imposed may be more
25		stringent than either the schedule limits on controlled substances established
26		in KRS 314.011(8) or the limits imposed in regulations promulgated by the
27		Kentucky Board of Nursing thereunder.

Page 6 of 13

22 RS HB 354/GA

<u>(i)[(k)]</u> Within thirty (30) days of obtaining a Controlled Substance Registration
 Certificate from the United States Drug Enforcement Administration, and
 prior to prescribing controlled substances, the advanced practice registered
 nurse shall register with the electronic system for monitoring controlled
 substances established by KRS 218A.202 and shall provide a copy of the
 registration certificate to the board.

7 (11) Nothing in this chapter shall be construed as requiring an advanced practice
8 registered nurse designated by the board as a certified registered nurse anesthetist to
9 enter into a collaborative agreement with a physician, pursuant to this chapter or any
10 other provision of law, in order to deliver anesthesia care.

11 (12) The jurisprudence examination shall be prescribed by the board and be conducted 12 on the licensing requirements under this chapter and board regulations and 13 requirements applicable to advanced practice registered nursing in this 14 Commonwealth. The board shall promulgate administrative regulations in 15 accordance with KRS Chapter 13A, establishing the provisions to meet this 16 requirement.

17	<u>(13)</u> (a)	Except as provided in subsection (14) of this section, before an advanced
18		practice registered nurse who wishes to continue to prescribe controlled
19		substances may discontinue or be exempt from a CAPA-CS required under
20		subsection (10) of this section, the advanced practice registered nurse shall
21		have completed four (4) years of prescribing authority for controlled
22		substances, while maintaining a CAPA-CS, United States Drug
23		Enforcement Administration registration, and a master account with the
24		electronic system for monitoring controlled substances established by KRS
25		<u>218A.202.</u>
26	<u>(b)</u>	On or after the effective date of this Act:

27 <u>1. An advanced practice registered nurse who has had four (4) years of</u>

1	prescribing authority with a CAPA-CS and who wishes to prescribe
2	controlled substances without a CAPA-CS shall submit, via the APRN
3	update portal, a request for review from the Kentucky Board of
4	Nursing that the advanced practice registered nurse's license is in
5	good standing;
6	2. The advanced practice registered nurse shall not prescribe controlled
7	substances without a CAPA-CS until the board has completed its
8	review and has notified the advanced practice registered nurse in
9	writing that the advanced practice registered nurse is exempt from the
10	CAPA-CS requirement; and
11	3. The review request shall include the payment of a fee set by the board
12	through the promulgation of an administrative regulation.
13	(c) Upon receipt of a request pursuant to this subsection, the Kentucky Board
14	of Nursing shall perform a review to determine whether the license of the
15	advanced practice registered nurse is in good standing based upon an
16	evaluation of the criteria specified in this subsection and in the
17	administrative regulation promulgated by the board pursuant to this
18	subsection, including but not limited to:
19	1. Verification that a current United States Drug Enforcement
20	Administration registration certificate for the advanced practice
21	registered nurse is on file with the board;
22	2. Verification that a current CAPA-CS notification for the advanced
23	practice registered nurse is on file with the board;
24	3. Verification that the advanced practice registered nurse has an active
25	master account with the electronic system for monitoring controlled
26	substances pursuant to KRS 218A.202;
27	4. Verification through a criminal background check of the absence of

1	any unreported misdemeanor or felony convictions in Kentucky; and
2	5. Verification through a check of the coordinated licensure information
3	system specified in KRS 314.475 of the absence of any unreported
4	disciplinary actions in another state.
5	(d) Based on the findings of these actions, the Kentucky Board of Nursing shall
6	determine whether or not the advanced practice registered nurse's license is
7	in good standing for the purpose of removing the requirement for the
8	advanced practice registered nurse to have a CAPA-CS in order to prescribe
9	controlled substances.
10	(e) If the advanced practice registered nurse's license is found to be in good
11	standing, the advanced practice registered nurse shall be notified by the
12	board in writing that a CAPA-CS is no longer required. The advanced
13	practice registered nurse shall not be required to maintain a CAPA-CS as a
14	condition to prescribe controlled substances unless the board later imposes
15	such a requirement as part of an action instituted under KRS 314.091(1).
16	An advanced practice registered nurse may choose to maintain a CAPA-CS
17	indefinitely after the determination of good standing has been made. An
18	advanced practice registered nurse who chooses to practice without a
19	CAPA-CS shall be held to the same standard of care as all other providers
20	with prescriptive authority.
21	(f) If the advanced practice registered nurse's license is found not to be in good
22	standing, the CAPA-CS requirement shall not be removed until the license
23	is restored to good standing, as directed by the board.
24	(g) The Kentucky Board of Nursing may conduct random audits of the
25	prescribing practices of advanced practice registered nurses, including
26	those who are no longer required to have a CAPA-CS in order to prescribe,
27	through a review of data obtained from the electronic system for monitoring

1	controlled substances pursuant to KRS 218A.202 and may take disciplinary
2	action under KRS 314.091(1) if a violation has occurred.
3	(14) (a) An advanced practice registered nurse wishing to practice in Kentucky
4	through licensure by endorsement is exempt from the CAPA-CS
5	requirement if the advanced practice registered nurse:
6	1. Has met the prescribing requirements for controlled substances in a
7	state that grants such prescribing authority to advanced practice
8	registered nurses;
9	2. Has had authority to prescribe controlled substances for at least four
10	(4) years; and
11	3. Has a license in good standing as described in subsection (13) of this
12	section and in the administrative regulation promulgated by the board
13	pursuant to subsection (13) of this section.
14	(b) An advanced practice registered nurse wishing to practice in Kentucky
15	through licensure by endorsement who has had the authority to prescribe
16	controlled substances for less than four (4) years and wishes to continue to
17	prescribe controlled substances shall enter into a CAPA-CS with a
18	physician licensed in Kentucky until the cumulative four (4) year
19	requirement is met, after which the advanced practice registered nurse who
20	wishes to prescribe controlled substances without a CAPA-CS shall follow
21	the process identified in subsection (13) of this section and in the
22	administrative regulation promulgated by the board pursuant to subsection
23	(13) of this section.
24	(15) An advanced practice registered nurse shall not prescribe controlled substances
25	without a CAPA-CS until the board has completed its review and has notified the
26	advanced practice registered nurse in writing that the advanced practice
27	registered nurse is exempt from the CAPA-CS requirement.

1		→SECTION 2. A NEW SECTION OF KRS CHAPTER 218A IS CREATED TO
2	REA	AD AS FOLLOWS:
3	<u>(1)</u>	There is hereby established the Controlled Substance Prescribing Review Panel
4		to provide investigations and referrals for action to the Kentucky Board of
5		Dentistry, the Kentucky Board of Medical Licensure, and the Kentucky Board of
6		Nursing.
7	<u>(2)</u>	The panel shall be located within the Office of the Inspector General in the
8		Cabinet for Health and Family Services.
9	<u>(3)</u>	The panel shall consist of:
10		(a) The inspector general, who shall act as chair;
11		(b) The executive director of the Kentucky Board of Dentistry;
12		(c) The executive director of the Kentucky Board of Medical Licensure;
13		(d) The executive director of the Kentucky Board of Nursing; and
14		(e) Three (3) licensed prescribers of controlled substances, of which one (1)
15		licensed prescriber shall be licensed by each the boards listed in subsection
16		(1) of this section. Each board shall provide to the Governor the names of
17		three (3) recommended licensees whose licenses are in good standing and
18		who currently prescribe controlled substances. The Governor shall appoint
19		one (1) of these recommended licensees as a representative of each board.
20	<u>(4)</u>	Support staff, facilities, and resources for the meetings and work of the panel
21		shall be provided by the inspector general, including three (3) full-time
22		investigators, with one (1) full-time investigator assigned to each of the three (3)
23		boards serving on the panel for the sole purpose of conducting investigations of
24		controlled substance prescribing by licensees governed by the board through
25		which they are licensed, the funding for which shall come from the 2022 opioid
26		<u>settlement fund.</u>
27	<u>(5)</u>	The panel shall:

1	(a) Review the quarterly reports issued by the Office of the Inspector General
2	pursuant to KRS 218A.202(17) that identify patterns of potential improper,
3	inappropriate, or illegal prescribing or dispensing of a controlled substance
4	and additional data from the electronic surveillance prescription drug
5	monitoring program established by the state;
6	(b) Initiate an investigation of any prescriber whose prescribing patterns are
7	identified as potentially improper, inappropriate, or illegal;
8	(c) Upon the completion of each investigation, forward the name of the
9	prescriber, a detailed description of the improper, inappropriate, or illegal
10	prescribing pattern, and the results of the investigation including any data,
11	expert review, or testimony collected to the board of jurisdiction so the
12	board shall take up the case for disciplinary action against the prescriber;
13	and
14	(d) Require a response from the board in writing within thirty (30) business
15	days from the receipt of the prescriber's name and investigative findings
16	and then every thirty (30) business days thereafter to the conclusion of the
17	case by the board. These responses shall include a description of the review
18	taken by the board and the disciplinary action taken or the reason for action
19	not being taken.
20	(6) The panel shall meet at regular intervals and no less than quarterly, and at the
21	call of the inspector general.
22	(7) Members of the panel shall be reimbursed for actual expenses incurred in
23	connection with the discharge of their official duties.
24	(8) The panel shall provide an annual report to the Governor and to the Legislative
25	Research Commission by December 1, 2022, and by December 1 of each year
26	thereafter which shall contain the following information for the previous year
27	regarding prescribing and dispensing of controlled substances:

1	(a) Number of prescribers referred to each licensure board;
2	(b) Aggregate number, types of violations, and types of disciplinary actions
3	taken by each licensure board;
4	(c) A list from each licensure board that includes the name of the prescriber,
5	the violation or violations, and the disciplinary actions taken;
6	(d) Reasons for not taking disciplinary action by each licensure board;
7	(e) Number of individual prescribers with multiple disciplinary actions taken by
8	their licensure board which included an action in the current year; and
9	(f) Timeliness of reports back to the panel by each licensure board for each
10	referred prescriber.
11	(9) The panel shall sunset on July 15, 2026, unless authorized by the General
12	Assembly to continue its work for a specified period of time.

Page 13 of 13